Single‐cell transcriptomics reveals antigen‐presenting capacity and therapeutic resistance potential of immunomodulatory endothelial cells in colorectal cancer
Immunity, Inflammation and Disease · 2024-06 · 12 (6)
DOI: 10.1002/iid3.1311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 14.06.2024. Verfasst von Jingyi Wen. Beteiligte Einrichtung: School of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Endothelial Cells, Single-Cell Analysis, Transcriptome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The heterogeneity of tumor endothelial cells (TECs) hinders the efficacy of antiangiogenic therapies (AATs). Only a small percentage of angiogenic TECs are considered effective targets for AATs. Immunomodulatory ECs (IMECs), as a newly focused functional subgroup of endothelial cells (ECs), are being evaluated for their ability to regulate tumor immune balance and influence existing AATs.
Methods
Based on single‐cell transcriptome data from colorectal cancer in a publicly available database, we conducted a wide array of bioinformatic approaches to study EC subsets that meet the IMECs definition. Our investigation encompassed the gene expression signatures of these subsets, cellular composition differences, cell–cell interactions.
Results
Two subsets that meet the IMECs definition were found in tumors and para‐cancerous tissues. Combined with the results of gene ontological analysis and interaction with CD4 + T cells, we found that IMECs can present MHC‐II antigens to mature CD4 + T cells. There were differences in the level of interaction between IMECs and different types of mature CD4 + T cell subsets. In addition, IMEC subsets had different expression levels of angiogenesis related genes. The angiogenesis score of IMECs decreased after patients received immunotherapy. IMEC subsets do not depend on a single proangiogenic receptor and are involved in regulating angiogenesis, which may reduce the efficacy of AATs. The adverse effects of specific IMEC subsets on AATs were validated in the RNA‐seq dataset of the bevacizumab treatment group.
Conclusion
Our study suggests the potential MHC‐II antigen presentation capacity of IMECs and the enhanced angiogenesis characteristics within tumors. The function of IMECs in the vascular network may have a potentially adverse effect on AATs. Controlling the functional properties of IMECs may be a new angle for tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong, China.
ORCID-Profile: Jingyi Wen
Zitieren
APA
Wen, J. (2024). Single‐cell transcriptomics reveals antigen‐presenting capacity and therapeutic resistance potential of immunomodulatory endothelial cells in colorectal cancer. Immunity, Inflammation and Disease, 12(6). https://doi.org/10.1002/iid3.1311
Vancouver
Wen J. Single‐cell transcriptomics reveals antigen‐presenting capacity and therapeutic resistance potential of immunomodulatory endothelial cells in colorectal cancer. Immunity, Inflammation and Disease. 2024;12(6). doi:10.1002/iid3.1311
BibTeX
@article{Wen2024,
author = {Wen, Jingyi},
title = {Single‐cell transcriptomics reveals antigen‐presenting capacity and therapeutic resistance potential of immunomodulatory endothelial cells in colorectal cancer},
journal = {Immunity, Inflammation and Disease},
year = {2024},
volume = {12},
number = {6},
doi = {10.1002/iid3.1311}
}
EUVIMED